Skip to main navigation Skip to search Skip to main content

25-NET-02-CPI (CRN00808-12): A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults with Carcinoid Syndrome due to Well-Differentiated Neuroendocrine Tumors

Grants and Contracts Details

StatusActive
Effective start/end date7/17/25 → 7/17/27

Funding

  • Crinetics Pharmaceuticals: $64,019.00